Linklaters advises Samsung BioLogics on the acquisition of full ownership of Samsung Bioepis in USD 2.3 billion deal
Linklaters advised Samsung BioLogics, a Korean company active in the development and manufacturing of biopharmaceutical products worldwide, in its agreement with Biogen (USA) to acquire its stake, and therefore full ownership, in the 50/50 Samsung Bioepis joint venture, a Korean company active in the development and commercialisation of biosimilar medicines. The aggregate consideration for this transaction is up to USD 2.3 billion. Bioepis is mostly active in Asia, Brazil, North America and in the EU.
Linklaters handled the filing of the transaction before the European Commission. The notification process was handled successfully and well in advance of standard deadlines as the operation was authorised on 4 April 2022. Samsung BioLogics was advised by the Korean premier law firm Kim & Chang on the other aspects of the deal, including the corporate side.
The Linklaters team in Paris was led by Anne Wachsmann (partner), Nicolas Zacharie (counsel) and Daniel Green (associate) for the Antitrust and Foreign Investment practice.